Managing the changing burden of cancer in Asia

BMC Medicine

You-lin Qiao³  Kunnambath Ramadas²  Rengaswamy Sankaranarayanan¹ 

[1] The International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon, Cedex 08, France;Regional Cancer Centre, PO Box 2417, Trivandrum 695011, Kerala State, India;Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

关键词: Survival;    Health services;    Clinical implication;    Treatment;    Diagnosis;    Early detection;    Screening;    Prevention;    Cancer burden;    Asia;   

Others  :  855189
DOI  :  10.1186/1741-7015-12-3

 received in 2013-05-21, accepted in 2013-12-12,  发布年份 2014

【 摘 要 】

Asia accounts for 60% of the world population and half the global burden of cancer. The incidence of cancer cases is estimated to increase from 6.1 million in 2008 to 10.6 million in 2030, due to ageing and growing populations, lifestyle and socioeconomic changes. Striking variations in ethnicity, sociocultural practices, human development index, habits and dietary patterns are reflected in the burden and pattern of cancer in different regions. The existing and emerging cancer patterns and burden in different regions of Asia call for political recognition of cancer as an important public health problem and for balanced investments in public and professional awareness. Prevention as well as early detection of cancers leads to both better health outcomes and considerable savings in treatment costs. Cancer health services are still evolving, and require substantial investment to ensure equitable access to cancer care for all sections of the population. In this review, we discuss the changing burden of cancer in Asia, along with appropriate management strategies. Strategies should promote healthy ageing via healthy lifestyles, tobacco and alcohol control measures, hepatitis B virus (HBV) and human papillomavirus (HPV) vaccination, cancer screening services, and vertical investments in strengthening cancer healthcare infrastructure to improve equitable access to services.

【 授权许可】

   
2014 Sankaranarayanan et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Nations U: World Population to 2300. United Nations: New York, NY; 2004.
• [2]Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P: Cancer Incidence in Five Continents Vol. IX. IARC Scientific Publications No. 160. International Agency for Research on Cancer: Lyon, France; 2007.
• [3]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer: Lyon, France; 2010.
• [4]Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M, Steliarova-Foucher E, Swaminathan R, Ferlay J: Cancer Incidence in Five Continents, Volume X. International Agency for Research on Cancer: Lyon, France; 2013.
• [5]Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F: Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012, 380:1840-1850.
• [6]Bray F, Jemal A, Grey N, Ferlay J, Forman D: Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 2012, 13:790-801.
• [7]Parkin DM, Whelan SL, Ferlay J, Storm H: Cancer Incidence in Five Continents Volumes I to VIII. IARC CancerBase No. 7. International Agency for Research on Cancer: Lyon, France; 2005.
• [8]Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
• [9]Zhang J, Dhakal IB, Zhao Z, Li L: Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev 2012, 21:480-489.
• [10]Pathy S, Lambert R, Sauvaget C, Sankaranarayanan R: The incidence and survival rates of colorectal cancer in India remain low compared with rising rates in East Asia. Dis Colon Rectum 2012, 55:900-906.
• [11]Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
• [12]Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, Lu L, Huang F, Zhu Y, Lu J, Ni Z, Zhang Q, Wu Y, Liu G, Wu Z, Qu C, Gail MH: Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013, 34:1800-1805.
• [13]Xie WC, Chan MH, Mak KC, Chan WT, He M: Trends in the incidence of 15 common cancers in Hong Kong, 1983–2008. Asian Pac J Cancer Prev 2012, 13:3911-3916.
• [14]Wiangnon S, Kamsa-ard S, Suwanrungruang K, Promthet S, Kamsa-ard S, Mahaweerawat S, Khuntikeo N: Trends in incidence of hepatocellular carcinoma, 1990–2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev 2012, 13:1065-1068.
• [15]Wu QJ: Vogtmann E, Zhang W, Xie L, Yang WS, Tan YT, Gao J, Xiang YB: Cancer incidence among adolescents and young adults in urban Shanghai, 1973–2005. PLoS One 2012, 7:e42607.
• [16]Teo MC, Soo KC: Cancer trends and incidences in Singapore. Jpn J Clin Oncol 2013, 43:219-224.
• [17]Guo B, Huang ZL: Esophageal cancer mortality trends in rural and urban China between 1987 and 2009. Asian Pac J Cancer Prev 2011, 12:2105-2110.
• [18]World Health Organization: National Cancer Control Programmes. Policies and Managerial Guidelines. Geneva: Switzerland: WHO; 2002.
• [19]Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO, Xiang YB, Yeole BB, Shin HR, Shanta V, Woo ZH, Martin N, Sumitsawan Y, Sriplung H, Barboza AO, Eser S, Nene BM, Suwanrungruang K, Jayalekshmi P, Dikshit R, Wabinga H, Esteban DB, Laudico A, Bhurgri Y, Bah E, Al-Hamdan N: Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010, 11:165-173.
• [20]Sankaranarayanan R, Swaminathan R: Cancer Survival in Africa, Asia, the Caribbean and Central America. IARC scientific Publications No. 162. International Agency for Research on Cancer: Lyon, France; 2011.
• [21]Sloan FA, Gelband H: Cancer Control Opportunities in Low- and Middle-Income Countries. Washington DC: National Academies Press; 2007.
• [22]IARC: IARC Monographs on the Evaluation of Carcinogenic Risks to Human. In Tobacco Smoke and Involuntary Smoking. IARC Monographs Volume 83. Lyon, France: International Agency for Research on Cancer; 2004.
• [23]Nations U: Statistical Yearbook for Asia and the Pacific 2011. Bangkok, Thailand: United Nations Publication; 2011.
• [24]Mannava P, Abdullah A, James C, Dodd R, Annear PL: Health systems and noncommunicable diseases in the asia-pacific region: a review of the published literature. Asia Pac J Public Healthin press
• [25]Au JS, Mang OW, Foo W, Law SC: Time trends of lung cancer incidence by histologic types and smoking prevalence in Hong Kong 1983–2000. Lung Cancer 2004, 45:143-152.
• [26]Adair T, Hoy D, Dettrick Z, Lopez AD: Reconstruction of long-term tobacco consumption trends in Australia and their relationship to lung cancer mortality. Cancer Causes Control 2011, 22:1047-1053.
• [27]Lim GH, Chow KY, Lee HP: Singapore cancer trends in the last decade. Singapore Med J 2012, 53:3-9.
• [28]Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, Sidibeh M, Jatta A, Moore SE, Hall AJ, Whittle H: Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One 2013, 8:e58029.
• [29]de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
• [30]Schiller JT, Castellsague X, Garland SM: A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl 5):F123-F138.
• [31]Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM: Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30(Suppl 5):F139-F148.
• [32]Access to HPV Vaccination: The HPV vaccination in Malaysia. http://www.essec.edu/fileadmin/user_upload/rubrique_Vie_etudiante/Campus/ESSEC-ASIA-Pacific/First-Health-Policy-Decision-Makers-Forum-Asia-Pacific/Saidaful-Buang_presentation-5.pdf webcite
• [33]Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F: H. pylori infection and gastric cancer: state of the art (review). Int J Oncol 2013, 42:5-18.
• [34]Asaka M: A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013, 132:1272-1276.
• [35]Yoo KY: Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 2008, 38:327-333.
• [36]Sankaranarayanan R, Thara S, Esmy PO, Basu P: Cervical cancer: screening and therapeutic perspectives. Med Princ Pract 2008, 17:351-364.
• [37]Su SY, Huang JY, Ho CC, Liaw YP: Evidence for cervical cancer mortality with screening program in Taiwan, 1981–2010: age-period-cohort model. BMC Public Health 2013, 13:13. BioMed Central Full Text
• [38]The Governement of Hong Kong Special Administrative Region of Republic of China: Cervical Cancer Screening Programme of Health. http://www.cervicalscreening.gov.hk/ webcite
• [39]Khuhaprema T, Attasara P, Srivatanakul P, Sangrajrang S, Muwonge R, Sauvaget C, Sankaranarayanan R: Organization and evolution of organized cervical cytology screening in Thailand. Int J Gynaecol Obstet 2012, 118:107-111.
• [40]Sankaranarayanan R, Nessa A, Esmy PO, Dangou JM: Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2012, 26:221-232.
• [41]Cuzick J, Bergeron C, von Knebel DM, Gravitt P, Jeronimo J, Lorincz AT, Meijer LM, Sankaranarayanan R, Snijders JF, Szarewski A: New technologies and procedures for cervical cancer screening. Vaccine 2012, 30(Suppl 5):F107-F116.
• [42]Moy LM, Zhao FH, Li LY, Ma JF, Zhang QM, Chen F, Song Y, Hu SY, Balasubramanian A, Pan QJ, Koutsky L, Zhang WH, Lim JM, Qiao YL, Sellors JW: Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer 2010, 127:646-656.
• [43]Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA: HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
• [44]Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT: A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9:929-936.
• [45]Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J: Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007, 370:398-406.
• [46]Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K: Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet 2003, 361:814-820.
• [47]Nessa A, Hussain MA, Rahman JN, Rashid MH, Muwonge R, Sankaranarayanan R: Screening for cervical neoplasia in Bangladesh using visual inspection with acetic acid. Int J Gynaecol Obstet 2010, 111:115-118.
• [48]Vet JN, Kooijman JL, Henderson FC, Aziz FM, Purwoto G, Susanto H, Surya IG, Budiningsih S, Cornain S, Fleuren GJ, Trimbos JB, Peters AA: Single-visit approach of cervical cancer screening: see and treat in Indonesia. Br J Cancer 2012, 107:772-777.
• [49]Sanghvi H, Limpaphayom KK, Plotkin M, Charurat E, Kleine A, Lu E, Eamratsameekool W, Palanuwong B: Cervical cancer screening using visual inspection with acetic acid: operational experiences from Ghana and Thailand. Reprod Health Matters 2008, 16:67-77.
• [50]National Cancer Centre of Korea: Cancer statistics. http://www.ncc.re.kr/english/infor/kccr.jsp webcite
• [51]Kwong A, Mang OW, Wong CH, Chau WW, Law SC: Breast cancer in Hong Kong, Southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients: 1997–2001. Ann Surg Oncol 2011, 18:3072-3078.
• [52]Okonkwo QL, Draisma G, Der KA, Brown ML, De Koning HJ: Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst 2008, 100:1290-1300.
• [53]Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P, Venugopal M, Anju G, Mathew BS: Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011, 103:1476-1480.
• [54]Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, Miller AB, Daniel EE, Gupta S, Uplap P, Thakur MH, Ramani S, Kerkar R, Ganesh B, Shastri SS: A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010, 126:976-984.
• [55]Pisani P, Parkin DM, Ngelangel C, Esteban D, Gibson L, Munson M, Reyes MG, Laudico A: Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer 2006, 118:149-154.
• [56]Shin A, Jung KW, Won YJ: Colorectal cancer mortality in Hong Kong of China, Japan, South Korea, and Singapore. World J Gastroenterol 2013, 19:979-983.
• [57]Khuhaprema T, Sangrajrang S, Lalitwongsa S, Chokvanitphong V, Raunroadroong T, Ratanachu-ek T, Muwonge R, Luca E, Wild P, Sankaranarayanan R: Organized colorectal cancer screening in Lampang Province, Thailand: preliminary results from a pilot implementation programme. BMJ Openin press
• [58]Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B: Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005, 365:1927-1933.
• [59]Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, Vinoda J, Ramadas K: Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Bull World Health Organ 2009, 87:200-206.
• [60]Choi KS, Jun JK, Park EC, Park S, Jung KW, Han MA, Choi IJ, Lee HY: Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One 2012, 7:e50041.
• [61]Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012, 307:2418-2429.
• [62]Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008, 9:279-287.
• [63]Yang S, Wu S, Huang Y, Shao Y, Chen XY, Xian L, Zheng J, Wen Y, Chen X, Li H, Yang C: Screening for oesophageal cancer. Cochrane Database Syst Rev 2012., 12CD007883
• [64]Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, Zhu YR: Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003, 10:204-209.
• [65]Ilic D, Neuberger MM, Djulbegovic M, Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev 2013., 1CD004720
• [66]Anderson BO, Cazap E, El Saghir NS, Yip CH, Khaled HM, Otero IV, Adebamowo CA, Badwe RA, Harford JB: Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 2011, 12:387-398.
• [67]Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
• [68]Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:1979-1987.
• [69]Stockton D, Davies T, Day N, McCann J: Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment. BMJ 1997, 314:472-475.
• [70]Elkin EB, Hudis C, Begg CB, Schrag D: The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999. Cancer 2005, 104:1149-1157.
• [71]Jatoi I, Anderson WF, Rao SR, Devesa SS: Breast cancer trends among black and white women in the United States. J Clin Oncol 2005, 23:7836-7841.
• [72]Kitano S, Kitajima M, Konishi F, Kondo H, Satomi S, Shimizu N: A multicenter study on laparoscopic surgery for colorectal cancer in Japan. Surg Endosc 2006, 20:1348-1352.
• [73]Okuno K: Surgical treatment for digestive cancer. Current issues - colon cancer. Dig Surg 2007, 24:108-114.
• [74]Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S: Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001, 48:225-229.
• [75]Okada K, Fujisaki J, Yoshida T, Ishikawa H, Suganuma T, Kasuga A, Omae M, Kubota M, Ishiyama A, Hirasawa T, Chino A, Inamori M, Yamamoto Y, Yamamoto N, Tsuchida T, Tamegai Y, Nakajima A, Hoshino E, Igarashi M: Long-term outcomes of endoscopic submucosal dissection for undifferentiated-type early gastric cancer. Endoscopy 2012, 44:122-127.
• [76]Green S, Bhandari P, DeCaestecker J, Barr H, Ragunath K, Jankowski J, Singh R, Longcroft-Wheaton G, Bennett C: Endoscopic therapies for the prevention and treatment of early esophageal neoplasia. Expert Rev Gastroenterol Hepatol 2011, 5:731-743.
• [77]Dunki-Jacobs EM, Martin RC: Endoscopic therapy for Barrett's esophagus: a review of its emerging role in optimal diagnosis and endoluminal therapy. Ann Surg Oncol 2012, 19:1575-1582.
• [78]Guimaraes M, Uflacker R: Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis 2011, 15:395-39x.
• [79]Lencioni R, Crocetti L: Image-guided ablation for hepatocellular carcinoma. Recent Results Cancer Res 2013, 190:181-194.
• [80]Waki K, Aikata H, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Takahashi S, Toyota N, Ito K, Chayama K: Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol 2010, 25:597-604.
• [81]Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013, 31:426-432.
• [82]Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004, 22:1454-1459.
• [83]Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin lymphoma. Lancet 2012, 380:848-857.
• [84]Bello C, Zhang L, Naghashpour M: Follicular lymphoma: current management and future directions. Cancer Control 2012, 19:187-195.
• [85]Moleti ML, Al-Hadad SA, Al-Jadiry MF, Al-Darraji AF, Al-Saeed RM, De VA, Piciocchi A, Uccini S, Foa R, Testi AM: Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. Pediatr Blood Cancer 2011, 56:560-567.
• [86]Vallabhajosyula S, Baijal G, Vadhiraja BM, Fernandes DJ, Vidyasagar MS: Non-Hodgkin's lymphoma: is India ready to incorporate recent advances in day to day practice? J Cancer Res Ther 2010, 6:36-40.
• [87]Greer JA, Jackson VA, Meier DE, Temel JS: Early integration of palliative care services with standard oncology care for patients with advanced cancer. CA Cancer J Clin 2013, 63:349-363.
• [88]World Health Organization: Cancer Pain Relief. Geneva, Switzerland: WHO; 1986.
• [89]Bingley A, Clark D: A comparative review of palliative care development in six countries represented by the Middle East Cancer Consortium (MECC). J Pain Symptom Manage 2009, 37:287-296.
• [90]McDermott E, Selman L, Wright M, Clark D: Hospice and palliative care development in India: a multimethod review of services and experiences. J Pain Symptom Manage 2008, 35:583-593.
• [91]Morita T, Kizawa Y: Palliative care in Japan: a review focusing on care delivery system. Curr Opin Support Palliat Care 2013, 7:207-215.
• [92]Tsuneto S: Past, present, and future of palliative care in Japan. Jpn J Clin Oncol 2013, 43:17-21.
• [93]Tatar M, Mollahaliloglu S, Sahin B, Aydin S, Maresso A, Hernandez-Quevedo C: Turkey. Health system review. Health Syst Transit 2011, 13:1-186.
• [94]Kwon S: Health care financing in Asia: key issues and challenges. Asia Pac J Public Health 2011, 23:651-661.
• [95]Shin JY, Kim SY, Lee KS, Lee SI, Ko Y, Choi YS, Seo HG, Lee JH, Park JH: Costs during the first five years following cancer diagnosis in Korea. Asian Pac J Cancer Prev 2012, 13:3767-3772.